The U.S. FDA cleared AbbVie’s antibody-drug conjugate Decnupaz (pivekimab sunirine) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval follows AbbVie’s 2023 acquisition of ImmunoGen, which supplied the CD123-targeting asset. The clearance for this aggressive, ultra-rare hematologic malignancy marks another ADC milestone for AbbVie’s post-merger oncology pipeline built around ImmunoGen’s platform. For BPDCN patients, the decision expands treatment options in a setting where therapeutic choices are limited. The approval also extends a theme of ongoing U.S. ADC adoption in difficult-to-treat blood cancers, reinforcing the commercial momentum ADC developers see when efficacy is paired with clear targeting.